JessicaH_TX said:Orforglipron is the more interesting oral story because it is not a peptide at all.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
The figures, for anyone assembling their own picture. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.
LabKate said:I do not accept that the fasting window is a minor inconvenience.
There is a second half to this that has not been said yet. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFollowing on from bbq_ray_KC — and this may be the naive question:
Whether the fasting requirement is as strict in practice as the label implies, and what people actually see when they get it wrong?
Closing the loop on my own question.
Update — I went back to the injectable. Not because the tablet did not work, but because the fasting window and my mornings were never going to agree.